Inclusion Criteria:  Male or females >18 years old ≥ 6months after kidney transplantation; Diagnosis of T2D or PTDM; HbA1c of 6.5% to 10%; eGFR ≥30 ml/min/1.73m^2 (as per the CKD-EPI equation); BMI ≤45kg/m^2; Blood pressure ≤160/90 and ≥90/60 at screening.  Exclusion Criteria:  Diagnosis of type 1 diabetes; Presence of severe peripheral vascular disease (i.e. prior amputation, gangrene, non-healing ulcer or ischemic rest pain); Presence of acute coronary syndrome, stroke or transient ischemic attack in the 3 months prior to screening; Prior episode of graft pyelonephritis in the 1 month prior to screening; Episode of acute graft rejection in the 3 months prior to screening; Initiation of a new immunosuppressive agent or discontinuation of an immunosuppressive agent in the 1 month prior to screening; Untreated urinary or genital tract infection; Severe hypoglycemia within 3 months of screening, or hypoglycemia unawareness; Pre-menopausal women who are nursing, pregnant, or of child-bearing potential and not practicing an acceptable method of birth control; Participation in another trial with an investigational drug within 30 days of informed consent; Alcohol or drug abuse within 3 months prior to informed consent that would interfere with trial participation; Any ongoing clinical condition that would jeopardize subject safety or study compliance based on investigator judgement. Patients currently using antipsychotic medications. Use of SGLT2 inhibitors within 1 month of starting the study.